Humira to Assume Lipitor's Crown As Pfizer Feels the Heat From Sanofi and Novartis

From Canada Newswire (June 28, 2011)

LONDON, June 28 /CNW/ - Rheumatoid arthritis treatment Humira will assume Lipitor's crown as the world's biggest selling drug, while Pfizer will cling on to its ranking as the biggest seller of prescription medicines through to 2016, according to the World Preview 2016 (second edition) report published today by EvaluatePharma, the premier provider of pharma and biotech analysis.

Lipitor's patent expiry this year precipitates the steepest decline in the industry's patent cliff, with $139bn predicted to be lost from sales of branded drugs between 2011 and 2016, equal to 20% of the global pharmaceutical market last year. Meanwhile the race for the pharmaceutical sales top spot is going to be close, with Sanofi and Novartis breathing down Pfizer's neck - all three companies are expected to have prescription drug sales in the region of $50bn by 2016, the EvaluatePharma report shows.

Clinging on

Despite predictions that sales of its prescription drugs are set to decline from $54.1bn last year to $51.2bn by 2016, Pfizer is expected to just cling on to the industry's top spot - but Sanofi and Novartis are catching up fast.

Sanofi's $20bn acquisition of Genzyme, predicted growth in emerging markets and its vaccines business have significantly boosted the outlook for the French group's pharmaceutical revenues - forecast sales in 2016 of $50.2bn are $11.2bn higher than in the same analysis conducted in April 2010.

Prospects for Novartis' pharmaceutical business have been boosted by key regulatory approvals for oral MS pill Gilenya and Tasigna, a follow-on product to leukaemia blockbuster Glivec.


    <<

                                                                    Change

                                                                      in

                                                             WW     Market

      WW Prescription (Rx)     WW Annual Sales   2016 vs.  Market    Rank

             Sales                  ($bn)        Apr-2010   Share   (10-16)

                                         Growth

    Rank  Company             2010 2016 (10-16)           2010 2016

     1    Pfizer              54.1 51.2   -1%      +4.0   8.0% 6.0%    -

     2    Sanofi              36.6 50.2   +5%     +11.2   5.4% 5.9%   +2

     3    Novartis            41.4 49.7   +3%      +2.6   6.1% 5.8%   -1

     4    GlaxoSmithKline     35.6 45.0   +4%      +6.3   5.3% 5.3%   +2

                                                   -0.3

     5    Roche               35.6 43.6   +3%             5.3% 5.1%    -

                                                   -4.0

     6    Merck & Co          40.4 42.3   +1%             6.0% 5.0%   -3

     7    AstraZeneca         32.1 27.0   -3%      +4.9   4.7% 3.2%    -

                                                   -1.7

     8    Abbott Laboratories 19.9 24.4   +3%             2.9% 2.9%   +2

     9    Teva Pharmaceutical 14.5 23.9   +9%      +3.1   2.1% 2.8%   +4

                                                   -2.9

     10   Johnson & Johnson   20.7 21.9   +1%             3.1% 2.6%   -1

Once again the fastest growing company in the top ten in terms of prescription revenues is expected to be Israeli company Teva. The generics firm is rapidly becoming a big pharma player through an aggressive M&A strategy which increasingly spans the industry spectrum from generics to innovative technologies. The EvaluatePharma report shows that Teva increased its share of the global generics market to 18% in 2010 and the company is well placed to benefit the most from the blockbuster patent cliff.

In contrast, the outlook for Merck & Co has been tempered somewhat, hit hardest by the phase III failure of novel anti-coagulant, vorapaxar. A year ago Merck was seen as Pfizer's closest rival for the top spot in 2016, but the company now sits outside the top five.

Humira reigns supreme

Estimated global sales of Lipitor of $10.6bn means 2011 will be the last year the cholesterol-lowering agent tops the rankings, with Humira expected to be the biggest selling medicine in 2012 with sales of $8.7bn. Humira is forecast to grow 5% annually to reach $9.7bn by 2016, almost $2bn higher than its nearest challenger, Roche's Avastin. The cancer antibody was once regarded as Lipitor's heir apparent before a number of clinical and regulatory setbacks in the last 18 months.

Biotech products targeting cancer and rheumatic disorders are seen accounting for six of the top ten products in 2016. Of the three small molecule drugs, AstraZeneca's cholesterol drug Crestor has been boosted by a successful legal defence of its patent until 2016. A receding generic threat in the US is benefitting Glaxo's respiratory medicine Advair, while Merck & Co's Januvia franchise goes from strength to strength and is expected to dominate the non-insulin market for diabetes agents.


 

                                                                       2016

                                                     WW Product     Change vs

       Top Ten Selling Products in 2016              Sales ($bn)      Apr-10

                                                                       %

    Rank Product  Company(s)  Target    Technology   2010 2016 Growth

                                        Biotech

                  Abbott +              (monoclonal

     1 Humira   Eisai       Arthritis antibody)    6.7  9.7  +5%   -405   -4%

                                      Biotech

                                      (monoclonal

     2 Avastin  Roche       Cancer    antibody)    6.2  7.8  +3%   -1078 -12%

                                      Biotech

                Roche +               (monoclonal

     3 Rituxan  Biogen Idec Cancer    antibody)    6.1  7.7  +3%   +897  +13%

                AstraZeneca           Conventional

                + Shionogi            (small

     4 Crestor  + Chiesi    Cholest-  molecule)    6.1  7.5  +3%   +1242 +20%

                Amgen +     erol      Biotech

                Pfizer +              (recombinant

     5 Enbrel   Takeda      Arthritis product)     7.3  7.2  -0%   -119   -2%

                GSK +                 Conventional

       Seretide Almirall +  Asthma /  (small

     6 / Advair Faes        COPD      molecule)    8.1  7.0  -2%   +1768 +34%

                                      Conventional

       Januvia /Merck + Ono           (small

     7 Janumet  + Almirall  Diabetes  molecule)    3.5  6.8  +10%  +791  +13%

                                      Biotech

                                      (monoclonal

     8 HerceptinRoche       Cancer    antibody)    5.2  6.5  +3%   +300   +5%

                J&J + Merck

                +                     Biotech

                Mitsubishi            (monoclonal

     9 Remicade Tanabe      Arthritis antibody)    6.5  6.1  -1%   +380   +7%

                                      Biotech

       Prevnar              Pneumoc-  (bioengineered

     10 13      Pfizer      occal     vaccine)     2.4  5.8  +13% +4081 +237%

                               diseas

    

Commenting on the launch of the report, Jonathan de Pass, founder and chief executive of EvaluatePharma, said: "Our revised outlook for 2016 shows how competitive the landscape will be for the big pharma players - key pipeline successes or failures, or the outcome of courtroom patent battles, could dramatically change the current picture".

"Our World Preview report provides valuable insight into life beyond the patent cliff and who the likely winners and losers will be".

EvaluatePharma launched the report today at BIO 2011 in Washington DC, United States.

More information on EvaluatePharma's World Preview 2016, which assesses forecasted trends in prescription drug sales, R&D spend, therapy area growth and the performance of marketed and pipeline products, can be found at EvaluatePharma's stand at BIO 2011 (3045) or via EvaluatePharma's website http://www.evaluatepharma.com

About EvaluatePharma (R) - http://www.evaluatepharma.com

Set up in 1996 by former top pharma analyst Dr. Jonathan de Pass, EvaluatePharma(R) is the premier source for pharma and biotech analysis.

EvaluatePharma was the first company to supply reliable consensus forecasts of global drug sales and now provides standardised worldwide financial and forecast models with consensus product forecasts to 2016, data on R&D pipelines, licensing deals, patent risk and M&A deals, along with analytical tools that include, Merge Company and Peer Group Analyzer and over 3000 global product NPVs (Net Present Value) linked to share price.

In 2007 EvaluatePharma(R)Alpha launched offering a valuation service designed to quantify market events and the impact on product, portfolio and company valuation - NPV Analyzer, Calendar of Events and the daily news service EP Vantage.


 

Posted: June 2011


View comments

Hide
(web2)